These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27604319)

  • 21. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.
    Pancera M; Shahzad-Ul-Hussan S; Doria-Rose NA; McLellan JS; Bailer RT; Dai K; Loesgen S; Louder MK; Staupe RP; Yang Y; Zhang B; Parks R; Eudailey J; Lloyd KE; Blinn J; Alam SM; Haynes BF; Amin MN; Wang LX; Burton DR; Koff WC; Nabel GJ; Mascola JR; Bewley CA; Kwong PD
    Nat Struct Mol Biol; 2013 Jul; 20(7):804-13. PubMed ID: 23708607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
    Utachee P; Isarangkura-na-ayuthaya P; Tokunaga K; Ikuta K; Takeda N; Kameoka M
    Retrovirology; 2014 Apr; 11():32. PubMed ID: 24758333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.
    Coss KP; Vasiljevic S; Pritchard LK; Krumm SA; Glaze M; Madzorera S; Moore PL; Crispin M; Doores KJ
    J Virol; 2016 Dec; 90(24):11132-11144. PubMed ID: 27707925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.
    Kong L; Lee JH; Doores KJ; Murin CD; Julien JP; McBride R; Liu Y; Marozsan A; Cupo A; Klasse PJ; Hoffenberg S; Caulfield M; King CR; Hua Y; Le KM; Khayat R; Deller MC; Clayton T; Tien H; Feizi T; Sanders RW; Paulson JC; Moore JP; Stanfield RL; Burton DR; Ward AB; Wilson IA
    Nat Struct Mol Biol; 2013 Jul; 20(7):796-803. PubMed ID: 23708606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
    Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK
    J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.
    Narayan KM; Agrawal N; Du SX; Muranaka JE; Bauer K; Leaman DP; Phung P; Limoli K; Chen H; Boenig RI; Wrin T; Zwick MB; Whalen RG
    PLoS One; 2013; 8(1):e52732. PubMed ID: 23326351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
    Gach JS; Quendler H; Tong T; Narayan KM; Du SX; Whalen RG; Binley JM; Forthal DN; Poignard P; Zwick MB
    PLoS One; 2013; 8(8):e72054. PubMed ID: 23991039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.
    Doran RC; Tatsuno GP; O'Rourke SM; Yu B; Alexander DL; Mesa KA; Berman PW
    PLoS One; 2018; 13(4):e0196370. PubMed ID: 29689099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody responses to the HIV-1 envelope high mannose patch.
    Daniels CN; Saunders KO
    Adv Immunol; 2019; 143():11-73. PubMed ID: 31607367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Stable MGAT1
    Doran RC; Yu B; Wright M; O'Rourke SM; Yin L; Richardson JM; Byrne G; Mesa KA; Berman PW
    Front Immunol; 2018; 9():2313. PubMed ID: 30344523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies.
    Moyo T; Ferreira RC; Davids R; Sonday Z; Moore PL; Travers SA; Wood NT; Dorfman JR
    Virology; 2017 Jan; 501():12-24. PubMed ID: 27846415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
    LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
    PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.
    Doores KJ; Fulton Z; Huber M; Wilson IA; Burton DR
    J Virol; 2010 Oct; 84(20):10690-9. PubMed ID: 20702629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.
    Rathore U; Saha P; Kesavardhana S; Kumar AA; Datta R; Devanarayanan S; Das R; Mascola JR; Varadarajan R
    J Biol Chem; 2017 Jun; 292(24):10197-10219. PubMed ID: 28446609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.
    Gram GJ; Hemming A; Bolmstedt A; Jansson B; Olofsson S; Akerblom L; Nielsen JO; Hansen JE
    Arch Virol; 1994; 139(3-4):253-61. PubMed ID: 7832633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
    Pantophlet R; Wilson IA; Burton DR
    J Virol; 2003 May; 77(10):5889-901. PubMed ID: 12719582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies.
    Qi Y; Jo S; Im W
    Glycobiology; 2016 Mar; 26(3):251-60. PubMed ID: 26537503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11.
    Moyo T; Ereño-Orbea J; Jacob RA; Pavillet CE; Kariuki SM; Tangie EN; Julien JP; Dorfman JR
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29618644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.